| Bid | 2.07 |
| Market Cap | 585.46M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -1.8 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2.25 |
| Volume | 1,395,176 |
| Avg. Volume (20D) | 1,894,103 |
| Open | 2.31 |
| Previous Close | 2.30 |
| Day's Range | 2.18 - 2.33 |
| 52-Week Range | 2.07 - 7.37 |
| Beta | undefined |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...
Analyst Forecast
According to 4 analyst ratings, the average rating for AUTL stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 377.27% from the latest price.
Next Earnings Release
Analysts project revenue of $300.00K, reflecting a n/a YoY growth and earnings per share of -0.21, making a -53.33% decrease YoY.
2 months ago · seekingalpha.com
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call TranscriptAutolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive ...